Florida CBD Market Insights under Farm Bill

Mar.04.2023
Florida CBD Market Insights under Farm Bill
Florida's CBD market grows after the "Farm Bill" passed in 2018, but regulations remain a challenge for industry insiders like Jordan.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not recommend any specific products and does not comment on any domestic policies related to the subject matter.


The legality of the products mentioned in the article only applies to their local overseas markets. Domestic readers are advised to take note and strictly adhere to relevant laws and regulations in China.


This article does not constitute any investment or consumption advice.


This article is not suitable for minors.


On the first day of the Asia Pacific Expo, 2FIRSTS conducted an exclusive interview with Jordan, a representative for CBD dealers in Florida. Jordan provided insights into the CBD market in the state of Florida.


The "Farm Bill" promotes the development of the marijuana market.


In 2014, the state of Florida passed the "Compassionate Medical Cannabis Act," which allowed some patients to use medical marijuana and low-THC cannabis.


What has truly fueled the booming CBD market in Florida is the Farm Bill introduced by the United States in 2018.


According to Jordan, this bill essentially opens the door for certain requirements to be met by marijuana products, with the most noteworthy aspect being the release of cannabinoids, including non-psychoactive cannabidiol (CBD), from federal regulation.


Jordan emphasized a key point to 2FIRSTS, stating that as long as the Delta-9 THC content is below 0.3%, it is classified as hemp rather than marijuana.


After the enactment of this law, products can be legally manufactured, sold, and transported as long as they comply with the federal regulations on ingredients limits and labeling requirements.


However, the implementation of regulations in different states may vary. For example, Florida has stricter regulations regarding marijuana. "First, one must have a lab that has a QR code to test all substances in the sample, including the levels of THC and CBD in marijuana, as well as testing for mold, heavy metals, and pesticides," said Jordan.


You never know when new regulations may be implemented.


Although there are existing regulations at the macro level, government regulation in response to the development of the CBD market is not set in stone and will be adjusted over time as new issues arise. For distributors like Jordan, it is important to ensure clear and transparent product ingredients and avoid any gray areas or potential bans.


Jordan stated, "Because you never know when there will be new regulations. The regulatory authorities could change the rules as early as tomorrow.


In recent years, the United States has become increasingly tolerant towards recreational marijuana. Jordan himself holds an optimistic view towards the potential future legalization of recreational marijuana in Florida, believing that it's only a matter of time. Data seems to support his optimistic outlook - as of February 2023, 21 states and Washington D.C. have legalized recreational marijuana, a stark contrast to the zero states that had done so prior to November 2011.


How will the market develop in the future?


From the perspective of someone who is focusing on CBD products, the rapid changes in the US consumer market are even difficult for industry insiders to predict. He cited the example of the rise of psychedelic mushrooms in the US market last year. Prior to this, there had never been such a product on the market, and no one could have predicted the emergence of this dark horse.


Jordan stated, "The industry is increasingly turning to psychedelic mushrooms and other alternative smoking products, while consumers are also placing greater attention on health.


According to Jordan, the CBD market in Florida has great potential for growth, especially with the gradual relaxation of marijuana regulations and increased awareness among consumers of health benefits. This may lead to an emergence of more innovative products and demand in the market.


However, for industry professionals, the challenge of operating in a constantly changing regulatory environment remains significant. Regardless of how the market may shift in the future, Jordan states that his focus will always be on providing high-quality CBD products to consumers.


2FIRSTS will continue to cover the APE exhibition and we look forward to bringing you the latest updates and reports.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Indonesia's Ministry of Industry said at a November 3, 2026, policy forum that the country has about 200 electronic cigarette companies, Rp31 trillion (approximately $1.71 billion) in cumulative industry investment and around 100,000 jobs across the supply chain. The National Narcotics Agency is seeking a comprehensive ban on vape use and circulation, while the industry ministry favors tighter import, product-standard and distribution controls. Indonesia exported approximately $518 million in vaping products in 2025, and Chinese manufacturers including Smoore, GEEKVAPE and Jinjia Group have established local operations. An international logistics specialist interviewed by 2Firsts said more Chinese vape companies began production in Indonesia from the second half of 2025, accompanied by increased shipments of manufacturing equipment and investment in logistics facilities. The regulatory debate comes as Indonesia expands its role in international vaping manufacturing.
Special Report
Nov.05
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07